Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Cyclically Adjusted Revenue per Share: ¥5.81 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600513 Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
63 GF Score
Price ¥16.64
GF Value ¥13.83
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Jiangsu Lianhuan Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Jiangsu Lianhuan Pharmaceutical Co SHSE:600513 -4.64% 63 Cyclically Adjusted Revenue per Share is ¥5.81 as of Mar. 2026. GuruFocus rates SHSE:600513 with a GF Score™ of 63/100 and a GF Value™ of ¥13.83 (Modestly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Jiangsu Lianhuan Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was ¥2.523. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥5.81 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Jiangsu Lianhuan Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 14.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Jiangsu Lianhuan Pharmaceutical Co was 15.00% per year. The lowest was 10.80% per year. And the median was 13.50% per year.

As of today (2026-08-21), Jiangsu Lianhuan Pharmaceutical Co's current stock price is ¥16.64. Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥5.81. Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.86.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Jiangsu Lianhuan Pharmaceutical Co was 7.94. The lowest was 1.69. And the median was 2.89.


Jiangsu Lianhuan Pharmaceutical Co  (SHSE:600513) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=16.64/5.81
=2.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Jiangsu Lianhuan Pharmaceutical Co was 7.94. The lowest was 1.69. And the median was 2.89.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Jiangsu Lianhuan Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Jiangsu Lianhuan Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Lianhuan Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Jiangsu Lianhuan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.48 3.98 4.45 4.90 5.60

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.06 5.22 5.42 5.60 5.81

SHSE:600513 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Lianhuan Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600513
63GF Score
Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Lianhuan Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jiangsu Lianhuan Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.523/116.3033*116.3033
=2.523

Current CPI (Mar. 2026) = 116.3033.

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.485 101.400 0.556
201609 0.584 102.400 0.663
201612 0.478 102.600 0.542
201703 0.507 103.200 0.571
201706 0.495 103.100 0.558
201709 0.620 104.100 0.693
201712 0.721 104.500 0.802
201803 0.852 105.300 0.941
201806 0.826 104.900 0.916
201809 0.876 106.600 0.956
201812 1.041 106.500 1.137
201903 0.885 107.700 0.956
201906 0.986 107.700 1.065
201909 1.144 109.800 1.212
201912 1.357 111.200 1.419
202003 1.069 112.300 1.107
202006 1.115 110.400 1.175
202009 1.218 111.700 1.268
202012 1.473 111.500 1.536
202103 1.175 112.662 1.213
202106 1.473 111.769 1.533
202109 1.431 112.215 1.483
202112 1.642 113.108 1.688
202203 1.463 114.335 1.488
202206 1.672 114.558 1.697
202209 1.841 115.339 1.856
202212 1.882 115.116 1.901
202303 1.597 115.116 1.613
202306 1.660 114.558 1.685
202309 1.931 115.339 1.947
202312 2.388 114.781 2.420
202403 1.786 115.227 1.803
202406 2.167 114.781 2.196
202409 1.743 115.785 1.751
202412 1.768 114.893 1.790
202503 2.178 115.116 2.200
202506 2.319 114.907 2.347
202509 2.616 115.471 2.635
202512 2.245 115.832 2.254
202603 2.523 116.303 2.523

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥5.81 mean?
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a Cyclically Adjusted Revenue per Share of ¥5.81 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors.
Is Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Jiangsu Lianhuan Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥5.81. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted Revenue per Share of ¥5.81 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. Jiangsu Lianhuan Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥5.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥13.83, compared to a current price of ¥16.64 — trading 20.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥5.81. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 63/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current Cyclically Adjusted Revenue per Share is ¥5.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥16.64 is trading 20.3% above its estimated GF Value™ of ¥13.83. GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600513:

  • Cyclically Adjusted Revenue per Share: ¥5.81
  • GF Value™: ¥13.83 vs. price of ¥16.64 (20.3% above fair value)
  • GF Score™: 63/100 with 10 warning signs

No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Lianhuan Pharmaceutical Co Business Description

Address No. 9, Jiankang 1st Road, Yangzhou Bio-Health Industry Park, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225127
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
63GF Score

Get the complete analysis for SHSE:600513

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.64
Price
¥13.83
GF Value